EPISODE · Dec 3, 2025 · 5 MIN
Eylea HD Approved for RVO and Extended Dosing
from Eyewire News: The Podcast · host Eyewire News
Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
Eylea HD Approved for RVO and Extended Dosing
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m